Keytruda (pembrolizumab) vs Margenza (margetuximab-cmkb)
Keytruda (pembrolizumab) vs Margenza (margetuximab-cmkb)
Keytruda (pembrolizumab) is an immune checkpoint inhibitor that targets the PD-1 receptor, widely used for various types of cancer, including melanoma, lung cancer, head and neck cancer, and others. Margenza (margetuximab-cmkb) is an anti-HER2 antibody designed to treat patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens. The choice between Keytruda and Margenza would largely depend on the type and characteristics of the cancer being treated; Keytruda is used for a broader range of cancers, while Margenza is specifically for certain breast cancer patients.
Difference between Keytruda and Margenza
Metric | Keytruda (pembrolizumab) | Margenza (margetuximab-cmkb) |
---|---|---|
Generic name | Pembrolizumab | Margetuximab-cmkb |
Indications | Various types of cancers including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and others | Metastatic HER2-positive breast cancer in combination with chemotherapy |
Mechanism of action | Programmed death receptor-1 (PD-1) blocking antibody | HER2/neu receptor antagonist monoclonal antibody |
Brand names | Keytruda | Margenza |
Administrative route | Intravenous infusion | Intravenous infusion |
Side effects | Fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain in extremity, and headache | Fatigue, nausea, diarrhea, vomiting, constipation, headache, fever, dizziness, weight loss, abdominal pain, and extremity pain |
Contraindications | Severe hypersensitivity to pembrolizumab or any of its excipients | Severe hypersensitivity to margetuximab-cmkb or any of its excipients |
Drug class | Anti-PD-1 monoclonal antibody | Anti-HER2 monoclonal antibody |
Manufacturer | Merck & Co. | MacroGenics, Inc. |
Efficacy
Keytruda (Pembrolizumab) Efficacy in Breast Cancer
Keytruda (pembrolizumab) is a monoclonal antibody that has been shown to be effective in treating certain types of breast cancer. Specifically, it is used for the treatment of patients with unresectable or metastatic, triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-approved test. The efficacy of Keytruda in breast cancer was demonstrated in a study known as KEYNOTE-355, which was a randomized, double-blind, phase 3 trial. In this trial, patients treated with Keytruda in combination with chemotherapy showed a significant improvement in progression-free survival compared to those who received chemotherapy alone. However, it is important to note that Keytruda is not indicated for all breast cancer patients and its use is contingent upon specific biomarker criteria.
Margenza (Margetuximab-cmkb) Efficacy in Breast Cancer
Margenza (margetuximab-cmkb), in combination with chemotherapy, is approved for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The approval of Margenza was based on the results of the SOPHIA study, a phase 3 clinical trial. In this study, patients receiving Margenza in combination with chemotherapy demonstrated a statistically significant improvement in progression-free survival compared to those receiving trastuzumab and chemotherapy. While the overall survival data were not mature at the time of the initial analysis, subsequent updates have suggested a potential improvement in overall survival with Margenza treatment.
Comparative Efficacy in Breast Cancer
When comparing the efficacy of Keytruda and Margenza in breast cancer, it is important to consider that they target different populations within breast cancer patients. Keytruda is used for PD-L1 positive, triple-negative breast cancer, which does not overexpress HER2, while Margenza is used for HER2-positive breast cancer. Therefore, the efficacy of these drugs cannot be directly compared as they are not used interchangeably. Each medication has shown efficacy in its respective indication and represents an important therapeutic option for patients with these specific types of breast cancer.
Conclusion
In conclusion, both Keytruda and Margenza have shown efficacy in the treatment of breast cancer, albeit in different subtypes of the disease. Keytruda has been effective in improving progression-free survival in certain patients with PD-L1 positive, triple-negative breast cancer when used in combination with chemotherapy. Margenza has demonstrated efficacy in patients with HER2-positive breast cancer who have previously received other anti-HER2 therapies, also showing an improvement in progression-free survival. The use of these drugs is a significant advancement in the personalized treatment approach for breast cancer, providing targeted therapies based on the tumor's specific characteristics.
Regulatory Agency Approvals
Keytruda
Margenza
Access Keytruda or Margenza today
If Keytruda or Margenza are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us